Mangoceuticals (MGRX) investor relations material

Executive summary

• Entered into a Business Combination Agreement with Nuclea Energy Inc., which will result in Nuclea shareholders owning ~96% of the combined entity post-transaction, pending regulatory and shareholder approvals.

• Revenues for Q2 2026 were $68,757, down from $168,109 in Q2 2025, reflecting a focus on website development and limited product launches.

• Net loss for Q2 2026 was $1.31 million, a significant improvement from $5.42 million in Q2 2025, mainly due to reduced stock-based compensation, legal, payroll, and investor relations expenses.

• The company continues to market men's wellness products via telemedicine, with a focus on ED, hair loss, hormone, and weight management therapies.

Financial highlights

• Q2 2026 revenue: $68,757 (Q2 2025: $168,109); six-month revenue: $136,621 (2025: $277,415).

• Q2 2026 net loss: $1,312,931 (Q2 2025: $5,415,820); six-month net loss: $4,716,072 (2025: $10,255,309).

• Cash as of June 30, 2026: $228,688 (Dec 31, 2025: $1,486,338).

• Working capital deficit of $1.2 million as of June 30, 2026.

• Accumulated deficit: $45.4 million as of June 30, 2026.

Outlook and guidance

• Management anticipates the need for additional funding to continue operations and support growth over the next 12 months.

• Plans to expand operations organically and through acquisitions, subject to funding availability.

• Strategic alternatives, including mergers and acquisitions, are being actively explored.